Paperpal Prime Logo

EUROPEAN UROLOGY : Impact Factor & More

eISSN: 1873-7560pISSN: 0302-2838

Key Metrics

Eigenfactor
0.05 - 0.1
Impact Factor
20 - 25
Scite Index
0.85 5-Year SI
SJR
Q1Urology
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on EUROPEAN UROLOGY

EUROPEAN UROLOGY Journal Specifications

Overview
Publisher ELSEVIER
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1975
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in EUROPEAN UROLOGY ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in EUROPEAN UROLOGY

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.
  • 30 Jun 2026
  • European urology
Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.
  • 30 Jun 2026
  • European urology
Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.
  • 29 Jun 2026
  • European urology
Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.
  • 29 Jun 2026
  • European urology
Reply to Andrew R. A. Godtman et al.'s Letter to the Editor re: The PROSA Trial: Some Prosaic Comments. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.036.
  • 25 Jun 2026
  • European urology
Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.
  • 24 Jun 2026
  • European urology
Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.
  • 30 Jun 2026
  • European urology
Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.
  • 30 Jun 2026
  • European urology
Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.
  • 29 Jun 2026
  • European urology
Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.
  • 29 Jun 2026
  • European urology
Reply to Andrew R. A. Godtman et al.'s Letter to the Editor re: The PROSA Trial: Some Prosaic Comments. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.036.
  • 25 Jun 2026
  • European urology
Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.
  • 24 Jun 2026
  • European urology

FAQs on EUROPEAN UROLOGY